BioDelivery Sciences International, Inc. (BDSI) Insider Sells $13,188.55 in Stock

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) insider Niraj Vasisht sold 6,905 shares of the business’s stock in a transaction dated Monday, January 30th. The stock was sold at an average price of $1.91, for a total transaction of $13,188.55. Following the sale, the insider now owns 178,727 shares in the company, valued at $341,368.57. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) opened at 2.05 on Monday. The stock has a 50 day moving average of $1.87 and a 200 day moving average of $2.19. BioDelivery Sciences International, Inc. has a 52-week low of $1.50 and a 52-week high of $4.39. The stock’s market capitalization is $110.94 million.

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

ILLEGAL ACTIVITY WARNING: “BioDelivery Sciences International, Inc. (BDSI) Insider Sells $13,188.55 in Stock” was published by sleekmoney and is the property of of sleekmoney. If you are accessing this story on another publication, it was stolen and reposted in violation of US & international copyright & trademark laws. The original version of this story can be accessed at http://sleekmoney.com/biodelivery-sciences-international-inc-bdsi-insider-sells-13188-55-in-stock/1658104.html.

Several institutional investors have recently added to or reduced their stakes in the stock. NEXT Financial Group Inc boosted its position in BioDelivery Sciences International by 42.4% in the third quarter. NEXT Financial Group Inc now owns 49,850 shares of the specialty pharmaceutical company’s stock valued at $135,000 after buying an additional 14,850 shares in the last quarter. Oxford Asset Management boosted its position in BioDelivery Sciences International by 280.8% in the fourth quarter. Oxford Asset Management now owns 107,945 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 79,599 shares in the last quarter. Acadian Asset Management LLC purchased a new position in BioDelivery Sciences International during the third quarter valued at $217,000. Searle & CO. purchased a new position in BioDelivery Sciences International during the third quarter valued at $455,000. Finally, Tiverton Asset Management LLC boosted its position in BioDelivery Sciences International by 206.1% in the third quarter. Tiverton Asset Management LLC now owns 180,417 shares of the specialty pharmaceutical company’s stock valued at $487,000 after buying an additional 121,468 shares in the last quarter. 53.57% of the stock is owned by institutional investors and hedge funds.

A number of analysts have commented on the stock. Roth Capital set a $6.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Monday, November 28th. FBR & Co set a $5.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Thursday, February 2nd. Zacks Investment Research downgraded shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Wednesday, October 19th. Finally, Cantor Fitzgerald set a $3.00 target price on shares of BioDelivery Sciences International and gave the stock a “hold” rating in a report on Thursday, December 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $5.00.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/biodelivery-sciences-international-inc-bdsi-insider-sells-13188-55-in-stock/1658104.html

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *